Baird served as co-manager on this offering
AboutSyndax Pharmaceuticals, Inc. (“Syndax” or the “Company”) (NASDAQ-GS:SNDX) recently completed an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $23.00 per share, which included the exercise in full by the underwriters of their option to purchase an additional 815,217 shares of common stock. The aggregated gross proceeds to Syndax from the offering are approximately $143.8 million.
Syndax is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s two lead product candidates are SNDX-5613 and SNDX-6352 (axatilimab). The Company is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged, acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. Syndax Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
CONTACT US TO LEARN MORE
- December 2020
- Syndax Pharmaceuticals, Inc.
- Target Location
- North America